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Abstract 
Background: Warfarin remains one of the most widely prescribed anticoagulants but is 
also a leading cause of adverse drug reactions. Genotype-guided warfarin dosing 
algorithms enable accurate dose estimation, potentially leading to improved safety and 
efficacy. However, genotype-guided dosing algorithms were developed primarily in 
populations of European descent and limited data are available regarding single 
nucleotide polymorphisms (SNPs) that significantly influence warfarin dose in Hispanic 
populations. 
 
Research Aim: The objective of this study was to determine whether clinical factors and 
SNPs previously associated with stable warfarin dose variability in populations of 
European and Hispanic descent accurately predicted warfarin stable dose in a Hispanic 
population. 
 
Study Design: Self-reported Hispanic and Latino patients on stable warfarin dose 
(defined as the same dose for at least two clinic visits separated by at least two weeks) 
were recruited. 
 
Methods: Candidate SNPs, including CYP2C9*2/*3, VKORC1-1639G>A, CYP4F2*3, 
and NQO1*2, were genotyped and clinical data were collected using a survey and the 
electronic medical record. Stepwise linear regression was performed to determine 
variables that significantly predicted square root of weekly warfarin dose. 
Results: A total of 76 patients of primarily Mexican American ancestry participated. All 
SNPs were within Hardy-Weinberg Equilibrium. The final stepwise regression model 
incorporated six variables, which explained 71% of the variability in warfarin weekly 
dose requirements. Significant predictors included weight (R2=0.287, p<0.0001), age 
(R2=0.143, p<0.0001), amiodarone use (R2=0.067, p=0.0005), and prior stroke 
(R2=0.025, p=0.02). Significant SNPs included VKORC1-1639A (R2=0.152, p<0.0001), 
and CYP2C9*2/*3 (R2=0.032, p=0.02). CYP4F2*3 and NQO1*2 did not significantly 
impact warfarin dose requirements despite previously published associations in 
Hispanic populations. 
Conclusion: These findings suggest that clinical and genetic predictors of warfarin 
weekly dose requirements are similar among populations of European descent and 
Hispanic populations with Mexican American ancestry. These results require replication 
and validation in independent cohorts with similar ethnicity, but advance our 
understanding of influences on warfarin dose variability among different race/ethnic 
groups. 
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Background 
Warfarin, also known as Coumadin, is the most prescribed oral anticoagulant in 
the United States (US) at 34 million prescriptions per year.1 Warfarin is primarily 
prescribed to prevent thrombosis in patients with atrial fibrillation, heart valve 
replacement, or risk factors for thromboembolic disease.2 
The functional discovery of warfarin has an interesting background. The 
Wisconsin Alumni Research Foundation (WARF) were tasked with establishing why 
local dairy cows were suddenly dying from the common dehorning procedure used for 
safety reasons. Following further investigation, the research team determined the cattle 
were eating spoiled sweet clover hay which contained a compound known as 
Dicoumarol.3 The blood-thinning compound was further derived into a more potent form 
called ‘warfarin’ and marketed as an effective rodenticide. Eventually, the blood thinning 
effects of warfarin were found to be reversed with vitamin K and its transition to clinical 
care took place in 1954.3 By 1978, warfarin inhibition of vitamin K epoxide reductase 
enzyme (VKORC1) was found to be the drug’s mechanism of action that caused 
thinning of the blood.4 Initial strategies to dose warfarin were largely based on clinical 
observation where population average doses to achieve stable warfarin therapy were 
approximately 5 mg/day.5 
As of today, warfarin remains a mainstay in anticoagulation therapy. Despite its 
effectiveness in reducing the risk of clotting, warfarin also causes severe bleeding and 
has been listed in the top 10 of the FDA’s Adverse Event Reporting System for the past 
several decades.6 Warfarin’s propensity to cause bleeding is partly due to the high inter-
individual variability in dose response. Clinical observations of warfarin therapy have 
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noted patients may require more than 10 fold differences in dose to achieve the same 
therapeutic anticoagulation.5  
Patients who begin warfarin therapy require close monitoring of their blood 
clotting level, which is measured by the International Normalized Ratio (INR).7 For most 
patients on long-term therapy, the INR goal is to reach a stable therapeutic blood 
clotting level between the levels 2 and 3, with healthy individuals having an INR of 
approximately 1. Patients with INR levels above 3 have increased risks of major 
hemorrhage while patients with INR levels below 2 experience increased risk of 
thromboembolism.  
Many factors are known to influence warfarin dose response and thereby 
interfere with the stability of therapeutic INR levels. Recent studies have found clinical 
and genetic factors that contribute to the variation in warfarin response between 
patients.8 Clinical factors known to affect warfarin dose response include age, gender, 
diet (i.e. leafy greens with high Vitamin K), interacting drugs, and body mass index. 
Genetic factors associated with warfarin dose variability include variants in genes that 
encode for proteins involved in warfarin metabolism and the vitamin K cycle. Instead of 
prescribing all patients a fixed starting dose of 5mg/day, which can lead to adverse 
events in some patients, clinical and genetic information known to affect warfarin dose 
may be harnessed to more accurately predict the right dose.  
The first half of this manuscript will detail the molecular aspects of vitamin K 
contribution to clotting, the enzymes that influence warfarin pharmacology, variants in 
genes that effect warfarin dose, and the considerations regarding race/ethnicity in 
genotype-guided warfarin dosing algorithms. The second half will describe the methods 
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and findings of my thesis project regarding the influence of warfarin dose requirements 
of 5 candidate single nucleotide polymorphisms (SNPs) in a clinical study of Hispanic 
patients on stable warfarin doses. Lastly, future directions and conclusions will be 
offered to explain the real-world impact the study will bring toward improving warfarin 
management to patients of Hispanic descent.  
Vitamin K Cycle and contribution to clotting 
Vitamin K is a necessary cofactor in converting upstream clotting factors to their 
active form. These vitamin K-dependent clotting proteins include factors II 
(prothrombin), VII, IX, and X.9 Once activated, the clotting factors contribute to both the 
intrinsic and extrinsic clotting cascades that will result in the formation of fibrin, the end 
product of the coagulation cascade. Fibrin contributes to stopping excessive bleeding 
that takes place in vascular endothelial cells by forming a stable mesh network around 
platelets. Individuals acquire the fat soluble vitamin K compound in two forms.9 Vitamin 
K1, also known as Phylloquinone is a natural molecule that is synthesized in green leafy 
plants such as cabbage, cauliflower, and spinach. Vitamin K2, or Menaquinone, is a 
form that is made by commensal gut flora and serves as an added vitamin K 
supplement to the dietary intake from green leafy vegetables.   
Following its intake, vitamin K will be absorbed along with fat chylomicrons into 
the bloodstream. From the bloodstream, vitamin K is transported into the liver along with 
low-density lipoprotein, where it can serve as a cofactor in the carboxylation and 
activation of the previously mentioned clotting factors. The clotting factors responsible 
for activating the downstream coagulation cascade are synthesized in the liver in the 
form of inactive precursor proteins known as prozymogens. To become active, these 
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clotting factors must be post-translationally modified through the carboxylation of 
glutamic acid residues. This reaction involves the conversion of glutamate (Glu) to 
carboxyglutamate (Gla) and is dependent on the enzyme gamma-glutamyl carboxylase 
(GGCX).9 
The carboxylation reaction mechanism takes place in the endoplasmic reticulum 
membrane space and involves a propeptide recognition site (amino acid 495-513) within 
the GGCX enzyme binding to a conserved 18 amino acid region within the clotting 
factor proteins.10 These conserved regions are located upstream of domain regions that 
contain the target glutamate (Glu) residues. Upon binding of the GGCX propeptide, a 
conformational change occurs which leads to increased affinity and binding of GGCX to 
vitamin K hydroquinone cofactor. The vitamin K hydroquinone cofactor is necessary in 
that it serves as the electron donor molecule. Following electron donation, vitamin K 
hydroquinone is oxidized to vitamin K2,3-expoxide. The electron donor transfer allows 
GGCX enzyme to catalyze the exchange of hydrogen on the glutamate residue for a 
carboxyl group, resulting in carboxyglutamate (Gla). This process will continue where 
the next unmodified glutamate (Glu) residue will take position in the GGCX enzyme 
active site and with the help of vitamin K hydroquinone cofactor, additional carboxylation 
of Glu residues will take place. When all of the Glu residues have been converted to Gla 
residues, the propeptide sequence of GGCX will decrease in affinity and the release of 
the active site from the clotting factors will occur. The activated clotting factors will then 
be transported to the plasma membrane of the hepatocyte through the Golgi transport 
system where they are exocytosed into the vascular system.10 
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Following the carboxylation of glutamic acid residues present in the peptide chains, the 
clotting factors will essentially contain two negative carboxyl groups on the peptide side-
chain.  The addition of the negative charge, provided by Gla, allows the clotting factor 
proteins to become active and induces their ability to bind calcium in the blood.10 The 
addition of calcium to the peptide chains, allows the clotting factor proteins to bind 
endothelial cell membrane components such as phospholipids. The binding of 
endothelial cells enables the clotting factors to localize to an area in the vascular system 
where damage to cell membranes and hemorrhaging is present. As a result, fibrin can 
be formed and the production of stable clots to stop bleeding will occur. A schematic of 
the vitamin K cycle is shown in Figure 1. 
Figure 1. The vitamin K cycle 
 
Furie B. N Engl J Med. 2013; 369(24):2345-6 
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Molecular mechanisms of important enzymes involved in vitamin K activation cycle 
In order for the continued activation of clotting factors to respond to future 
bleeding events, oxidized vitamin K2,3-epoxide must be recycled back to its reduced 
hydroquinone form through the vitamin K cycle.9 It is well known in the event of 
diminished vitamin K presence or activity, either through hereditary or environmental 
conditions like malabsorption, carboxylation of glutamate residues on clotting factors will 
not take place. Due to the inactivation of clotting factors, severe bleeding events can 
take place and may be reversed with high doses of vitamin K. However, in normal 
processing of the vitamin K cycle, the oxidized form, vitamin K2,3-expoxide, will be 
reduced to vitamin K1 (quinone form), which is catalyzed by vitamin K epoxide 
reductase (VKORC1) enzyme.  
Upon uptake into hepatocytes or from reduction by VKORC1, vitamin K1 
quinone, which represents the natural form in blood such as Phylloquinone or 
Menaquinone, will be further reduced to vitamin KH2, a reduced quinone form known as 
hydroquinone. In this reaction, two hydrogens are added to the carbonyl oxygens 
located on the quinone group. The reduction and transfer of the hydrogen atoms that 
initiates the change from K1 to KH2 can be catalyzed by either VKORC1 (in this case 
vitamin K reductase) or NAD(P)H quinone dehydrogenase 1 (NQ01) and can be 
additionally facilitated by the donation of hydrogens in dithiol groups such as 
glutathione. Through this feedback-loop cycle, oxidized vitamin K can be recycled back 
to the active hydroquinone form KH2 where it can participate as a necessary cofactor in 
the activation of additional clotting factors through carboxylation of glutamate peptide 
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residues by gamma-glutamyl carboxylase (also called vitamin K-dependent 
carboxylase).9 The integrated vitamin K cycle process is shown above in Figure 1. 
Additional enzymes that also play a role in the regulation of the vitamin K cycle 
include Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) and calumenin 
(CALU). CYP4F2 contributes as a counter regulator to VKORC1 by oxidizing excess 
vitamin K1 into a hydroxy-vitamin K derivative.11 The proposed function of CYP4F2 is to 
serve as a way to limit the excess accumulation of vitamin K1, possibly resulting from 
diets high in vitamin K. Calumenin protein is found in the endoplasmic reticulum where 
GGCX and VKORC1 also localize. CALU may play a role in regulating the activity of 
GGCX through the inhibition of both GGCX and VKORC1.12 The contribution of these 
essential enzymes to the vitamin K cycle is shown in Figure 2.  
Figure 2. Genes coding for important enzymes involved in the Vitamin K cycle and 
warfarin metabolism 
 
Kaye et al. Pharmacotherapy 2017; 37: 1150–63 
Warfarin pharmacological effects on VKORC1 and warfarin metabolism 
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Warfarin elicits is anticoagulant effect by preventing the reduction of the oxidized 
vitamin K2,3-epoxide form to the reduced vitamin K1 form through inhibition of vitamin K 
epoxide reductase (VKORC1). This prevents the formation of vitamin KH2 cofactor and 
thus its participation with gamma-glutamyl carboxylase (GGCX) in activating clotting 
factors. A recent study by Czogalla et al. presented a mechanism for VKORC1 inhibition 
where warfarin competes with vitamin K2,3-epoxide for the same Phe55 phenyl side 
chain located in a hydrophobic pocket active site within VKORC1.13 When VKORC1 is 
in an oxidized conformation, warfarin has greater affinity to bind, which induces a further 
conformational change in which Phe55 will localize deeper in the hydrophobic pocket, 
making it less likely for vitamin K2,3-epoxide to bind. In this conformational state, 
warfarin is tightly bound to VKORC1 and supported by cysteine-loop clamps that hold 
warfarin in the active site.  
The presence of protein disulfide isomerase located in the endoplasmic reticulum 
will reduce the cysteine loops and cause VKORC1 to shift to a reduced conformation 
where the loop clamps on warfarin will be loosened and allow the release of warfarin 
and the exposure of Phe55. The reduced form of VKORC1 and exposed active site of 
VKORC1 will attract the binding of vitamin K2,3-epoxide. Next, the reduced cysteine 
loops will transfer electrons to the active site where vitamin K2,3-epoxide will be 
reduced to vitamin K1 quinone. vitamin K1 quinone can also bind to VKORC1 in the 
same manner and will be reduced to vitamin KH2. The proposed molecular pathway of 
VKORC1 inhibition followed by competitive binding by vitamin K2,3-epoxide is shown in 
Figure 3.13 This recent proposed mechanism of VKORC1 binding by competitive 
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inhibition parallels clinical observation where high doses of vitamin K can effectively 
reverse the effects of over-anti coagulation by warfarin. 
Figure 3. Warfarin and vitamin K compete for binding to Phe55 in VKORC1 
 
Czogalla et al. Nat Struct Mol Biol 2017; 24: 77–85 
The metabolism of the more potent S-enantiomer of warfarin to an inactive 
hydroxy metabolite is carried out by cytochrome P450 family 2 subfamily C member 9 
(CYP2C9).14 Upon oral intake, warfarin is hydrolyzed to its R and S enantiomer forms in 
the gut and absorption along with fat chylomicrons into the systemic circulation occurs 
at the level of the small intestine. Warfarin enters the liver during first past metabolism 
and exerts its anticoagulant effect on VKORC1 and in addition metabolizes to an 
inactive state by CYP2C9 enzymes, which are primarily located in the liver. 
Variants in vitamin K cycle genes that affect warfarin dose response 
Both enzymes, VKORC1 and CYP2C9, directly interact with warfarin and thus 
are the main contributors that can influence warfarin dose and warfarin anticoagulation 
response in patients receiving warfarin therapy.15 Inherited single nucleotide 
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polymorphisms (SNPs) in the genes that encode VKORC1, CYP2C9 and variants in 
additional genes involved in the vitamin K cycle such as NQ01, CYP4F2, GGCX, and 
CALU are known to be one of the primary causes for the wide variability in interpatient 
warfarin dose requirements.16 It is estimated that clinical factors account for ~20 percent 
and genetic factors account for ~40 percent of the variation in warfarin dose response.17 
The remaining 40 percent is still unknown and may include the contribution of factors 
such as epigenetics, insertions, deletions, duplications, proteomic, and metabolomic 
interactions. The estimated percent contributions of these factors to warfarin dose 
response is shown in Figure 4.  
Figure 4. Factors contributing to variation in warfarin response 
 
 
Baker et al. Curr Opin Pharmacol 2016; 27: 38–42 
In terms of CYP2C9 SNPs that affect warfarin dose, variants CYP2C9*2 and 
CYP2C9*3 were reported to decrease CYP2C9 activity in comparison to the wild-type 
(normal) allele CYP2C9*1.18 The reduced activity of CYP2C9 in carriers of these 
variants were confirmed, in that homozygous patients with genotypes (*2/*3 or *3/*3) 
required up to a 28 percent reduction in mean weekly dose compared to wild-type 
patients (*1/*1).19 These variants reduce the ability of CYP2C9 to metabolize warfarin 
and the patients who were carriers of these variant alleles became more warfarin 
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sensitive and required lower doses of warfarin to achieve stable anticoagulation. 
Regarding CYP2C9*2, a DNA nucleotide base pair change from cytosine to thymine at 
position 430 in the exon 3 coding region resulted in an amino acid substitution of 
arginine for cysteine. In CYP2C9*3, a nucleotide substitution of adenine for cytosine at 
position 1075 in the exon 7 coding region resulted in an amino acid substitution of 
isoleucine for leucine. These non-synonymous missense mutations were not located 
directly within the active site of CYP2C9, however, recent proteomic modeling studies 
have shown the amino acid substitutions cause a decreased binding affinity of warfarin 
toward CYP2C9.19  
The presence of CYP2C9*2 and *3 variants induce a conformational change 
where hydrogen bonding interactions between CYP2C9 and warfarin are disrupted in a 
proportional manner to the number of variants. For example, as shown in Figure 5, a 
total of either 3, 1, or no hydrogen bonds will be present in patients who have a wild-
type (*1/*1), heterozygous (*1/*2 or *1/*3) or homozygous (*2/*3) CYP2C9 genotype, 
respectively. These findings provide further molecular-based evidence to suggest the 
variants cause a reduction in metabolism of warfarin due to the decreased affinity 
binding to warfarin. Additional CYP2C9 variants such as CYP2C9*5,*6,*8, and, *11 
alleles have also been identified that cause reduced activity and increased sensitivity to 
warfarin.20 
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Figure 5. Protein-ligand interactions with reference to CYP2C9 variants 
  
Pavani et al. Pharmacogenomics 2015; 16: 393–400 
In terms of VKORC1 polymorphisms, VKORC1-1639G>A has been identified as 
a primary variant that contributes to warfarin dose response. In contrast to the CYP2C9 
variants, which confer a reduction in activity, the variant in VKORC1 is located in an 
upstream promoter region of the gene and instead affects the expression and the 
abundance of VKORC1 protein. Individuals who are carriers of the -1639A allele have 
decreased VKORC1 protein and thus reduced maintenance warfarin dose requirements 
compared to the wild-type -1639G allele. The clinical impact is that individuals 
heterozygous for the A allele required 13 mg less warfarin per week, while homozygous 
individuals required 23 mg less warfarin per week than those with the GG genotype.21 
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These findings were substantiated in a second study that resulted in a 2-fold lower 
expression of VKORC1 mRNA in carriers of the -1639A allele.21 The exact molecular 
mechanism showing how a guanine to adenine substitution may reduce expression has 
yet to be illustrated. However, this substitution creates an E-box binding site in the 
promoter region of VKORC1 where E-box binding proteins can bind and suppress 
transcription, and thus abundance of the protein.21  
Additional SNPs found to affect warfarin dose, although in a less substantial 
manner to VKORC1 and CYP2C9, include polymorphisms in CYP4F2, NQO1, GGCX, 
and CALU. The CYP4F2*3 variant leads to a V433M amino acid change and reduced 
enzyme activity.11 The loss of activity confers the limited ability to oxidize vitamin K1 and 
remove excess vitamin K from the vitamin K cycle, which results in more vitamin K able 
to become activated and initiate clotting. This is confirmed by the increased resistance 
to warfarin therapy and higher doses of warfarin needed to achieve stable 
anticoagulation in patients with the CYP4F2*3 allele. The finding of no measured 
differences in mRNA expression levels in human hepatocytes between wild-type and 
variant allele carriers further suggests the V433M amino acid substitution does not 
affect transcription but rather enzyme activity.22 
 A cytosine to thymine substitution in the exon region encoding NQO1 causes a 
proline to serine substitution in the amino acid position 187, which is denoted as 
NQO1*2 allele.23 The amino acid change has been shown to destabilize and reduce the 
function of the allele and has been confirmed in homozygous carriers who require 
reduced warfarin maintenance dose.24 A loss of function variant has also been reported 
in the gene CALU, which corresponds to a 11% to 15% higher warfarin dose 
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requirement.25 The presence of the GGCX (CAA) 16/17 repeat variant resulted in a gain 
of function and an increase in warfarin dose requirements compared to the wild-type 
form.26 
Warfarin Pharmacogenomics and consideration of race/ethnicity 
Based on the mounting evidence that genetic variation influences warfarin dose 
response, interest in using genetic tests to personalize warfarin dosing has increased 
greatly. Due to the wide inter-individual variation in dose response to reach therapeutic 
INR levels, shifting from a ‘one-size fits all’ dosing strategy to a dosing strategy that 
incorporates personal genetic and clinical data makes clinical sense. The development 
of genotype-guided warfarin dosing algorithms may allow improved warfarin dose 
prediction and increase the safety and efficacy during the early course of warfarin 
therapy. Researchers focused on warfarin pharmacogenomic implementation have 
developed several common algorithms. Algorithms developed by the International 
Warfarin Pharmacogenomics Consortium (IWPC) and Gage et al. primarily serve as the 
recommended warfarin dosing guidelines.15,27 However, these algorithms were 
developed in populations of primarily European ancestry and at the time of 
development, only included the genetic variants CYP2C9*2/*3 and VKORC1-1639A 
along with clinical data.  
The clinical utility of the IWPC and Gage algorithm were examined and both 
showed improved accuracy in predicting stable warfarin dose compared to fixed-dosing 
and clinical dosing methods. However, as mentioned, these clinical studies consisted of 
a patient population that was predominately European. Moreover, in a landmark study 
published in the New England Journal of Medicine including a more diverse patient 
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population, the performance of genotype-guided dosing in predicting stable warfarin 
dose was significantly lower than clinically-guided dosing in patients who self-identified 
as African American (time in therapeutic range was 35.2% vs 43.5%, respectively 
p=0.0003).28 The findings from this clinical study suggested using European genetic 
data to guide dosing may potentially harm patients with African ancestry and these 
genotype-guided European based algorithms may not be effective in predicting warfarin 
dose for African-American patients. The inaccuracy of these algorithms are likely to 
extend to other diverse populations.29 
Moving forward, the consideration of race/ethnicity in the implementation of 
genetic-guided dosing will be critical. Recent studies included a severe under-
representation of non-European groups including Hispanic, American Indian/Alaska 
Native, and to a lesser extent, African Americans.29 Furthermore, non-white populations, 
in particular African Americans and Hispanics, experience greater sub-optimal warfarin 
management and greater warfarin-related adverse events compared to European 
patients.30,31 These findings suggest diverse populations potentially have the most to 
gain from genetic studies that are focused on discovering novel variants that affect 
warfarin dose requirements in other race/ethnic groups. 
Race/ethnicity-based genetic diversity contributing to warfarin dose variability 
In addition to the wide inter-patient variability in warfarin dose needed to achieve 
stable anticoagulation, the average warfarin dose required also differs by race/ethnicity. 
The daily doses needed to achieve stable INR levels is estimated at 5.1 mg in European 
patients, 5.7 mg in patients with African ancestry, 4.4 mg in Hispanic patients, 3.4 mg in 
Asian patients, and 4.5 mg in American Indian/Alaska Natives (AI/ANs).32 Because 
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variants will have biologically similar effects on warfarin dose across populations, one of 
the primary drivers responsible for the differences in warfarin dose requirement between 
race/ethnic groups may be attributed to how common warfarin variants are found within 
different populations. For example, the warfarin sensitive allele VKORC1-1639A is 
found at a frequency of 88% in Asian populations compared to a frequency of 5% in 
populations with African ancestry (Figure 6). These differences may partially contribute 
to the lower average daily warfarin dose requirements observed in Asian populations 
and higher average daily warfarin dose requirements observed in African American 
populations. 
 The presence of race-specific variants may also contribute to differences in 
warfarin dose requirements between race/ethnic groups. For example, CYP2C9*2 and 
*3 warfarin sensitive variants are the most common in Europeans while warfarin 
sensitive variants CYP2C9*5,*6,*8, and *11 exist in individuals with African descent but 
are essentially non-existent in the other populations as shown in Figure 6.33  
 
 
 
 
 
 
 
 
 
   
 
22 
 
Figure 6. Genetic variants that contribute to warfarin dose and their frequencies by race 
 
Kaye et al. Pharmacotherapy 2017; 37: 1150–63 
 
Hispanic Specific variants that affect warfarin dose response 
Hispanic individuals represent one of the most diverse race/ethnic groups. This 
genetic diversity is illustrated through the wide variation in individual admixture 
proportions of European, Native American, and African ancestry, which is largely tied to 
geographical location.34 In the limited warfarin genetic studies aimed at evaluating 
genetic contributions to warfarin dose in Hispanics, the addition of the more prevalent 
CYP4F2*3 and NQO1*2 variants improved the explanation of warfarin dose variability 
by 10 percent.35 In addition, the performance of algorithms developed in populations of 
Hispanic ancestry explained warfarin dose variability more accurately than the 
European-based IWPC or Gage algorithm when more common Hispanic variants such 
as CYP4F2*3 were incorporated.36 
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Interestingly, a study of Hispanic Mexican Americans found NQO1*2 allele 
carriers had an increased warfarin dose requirement, which was in contrast with earlier 
findings that showed the variant caused a decreased warfarin dose requirement in 
European and Asian patients.35 Because the biological explanation agrees on how 
NQO1*2 variants result in lower warfarin dose requirements, as described previously, it 
is suggested that NQO1*2 may be inherited with an unknown causative variant that is 
not present in other race/ethnic groups. Given the rich diversity in differences in 
Hispanic ancestry, genetic studies limited to a majority population may fail to capture 
variants that predict warfarin dose for this population.  For example, genotype-guided 
warfarin algorithms in Hispanic patients with greater percentages of Native American 
ancestry may be less effective due to the limited genetic knowledge and the possibility 
of missing important variants that affect warfarin dose in Native American populations. 
In addition, the majority of Hispanic-specific studies that are developing algorithms 
primarily focus on replicating associations of known variants rather than focusing on 
identifying novel variants that may improve prediction of warfarin dose.  
Thesis Hypothesis 
The vast majority (> 80%), of warfarin genotype-guided studies have been 
performed in populations of European ancestry.29 The implementation of genotype-
guided algorithms to improve the prediction of optimal warfarin dosing for patients is 
encouraging, however, the current genetic factors primarily encompass traditional 
variants (SNPs) found predominately in European populations. This critical 
underrepresentation of diverse populations in warfarin studies may contribute to a lack 
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of identification of important variants specific to race/ethnic groups that may be non-
existent in European populations. 
In a prospective clinical study, we examined candidate gene SNPs in CYP2C9, 
VKORC1, CYP4F2, and NQO1 in 76 self-identified Hispanic patients to determine the 
influence of these variants on warfarin stable dose requirements. The variants selected 
included the primary European-based warfarin predictors VKORC1-1639A and CYP2C9 
*2/*3 alleles.15,37 In addition, SNPs CYP4F2*3 and NQO1*2 shown previously to 
influence dose in a Hispanic population, were examined along with non-genetic 
variables known to predict warfarin dose.36,38 We hypothesize incorporation of SNPs 
VKORC1-1639A and CYP2C9 *2/*3 in a Hispanic population will have similar 
contributions to the European-based Gage model in explaining variability in warfarin 
dose requirements. Furthermore, the addition of SNPs CYP4F2*3 and NQO1*2 will 
improve warfarin dose prediction above and beyond the Gage algorithm, which only 
considered the common VKORC1-1639A and CYP2C9 *2/*3 variants. 
Methods 
 
A total of 76 self-reported Hispanic and Latino patients on stable doses of 
warfarin were recruited between October 2016 and March 2018. Recruitment took place 
at the Banner University Medical Center-Tucson Sarver Heart Center Coumadin Clinic 
and El Rio Community Health Center in Tucson, Arizona. Subjects were provided 
written informed consent approved by the University of Arizona Internal Review Board.  
Inclusion Criteria were 1) at least 18 years of age; 2) ability to give informed consent; 3) 
therapeutic INR for at least 2 consecutive clinic visits (separated by at least two weeks); 
   
 
25 
 
and 4) self-identifies as Hispanic or Latino. Exclusion criteria were 1) less than 18 years 
of age; 2) unable to give informed consent and 3) severe hepatic impairment. 
Demographic data was obtained in an interview with the participant as well as 
retrospectively from the electronic health record and included age, gender, height, 
weight, race/ethnicity, national origin, smoking status, alcohol status, INR 
measurements, target INR range, concurrent medications, and indication for warfarin 
therapy as shown in Table 1.  
Table 1. Study Population Characteristics in Hispanic Patients treated at Banner 
Medical Center/El Rio Community Health Center in Tucson, Arizona 
Study Population Characteristics                                     Total (n=74)a  
Stable warfarin dose (mg/week)   
Mean  33.8 (14.8) 
Range 9.5-70 
Age (years)  
Mean  65.8 (16.9) 
Range 26-91 
Weight (lbs.)  
Mean  200.0 (64.4) 
Range 98-477 
Height (inches)  
Mean  65.4 (3.64) 
Range 55-74 
BMI   
Mean  32.7 (9.58) 
Range 19-77 
Gender  
Male 41 (55.4) 
Race/Ethnicity  
Hispanic/Latino  74 (100) 
White 18 (24.3) 
American Indian/ Alaska Native  4 (5.41) 
Indication(s)  
Tobacco status 9 (12.2) 
Alcohol status 10 (13.5) 
Deep vein thrombosis 23 (31.1) 
Pulmonary embolism 13 (17.6) 
Stroke 7 (9.46) 
Atrial fibrillation 38 (51.4) 
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Prosthetic Valve 16 (21.6) 
Concomitant medications  
Statin 41 (55.4) 
Amiodarone 4 (5.41) 
Sulfamethoxazole 1 (1.35) 
BMI= body mass index. 
a Continuous data presented as mean (±SD), dichotomous data presented as n (%). 
 
A 30-milliliter mouthwash sample was obtained from each patient during a 
routine clinic visit. Genomic DNA was extracted and purified from the mouthwash 
sample using Puregene© Blood Kit from QIAGEN following the manufacturer’s protocol. 
The DNA was quantified by a NanoDrop spectrophotometer and fluorescent staining of 
dsDNA using PicoGreen® dsDNA Quantification Kit. Following DNA purification, 
genotyping of VKORC1, CYP2C9, CYP4F2 and NQO1 at 5 variable regions (2 SNPs in 
CYP2C9) were performed using TaqMan analysis at the University of Arizona Genetics 
Core. 
In order to determine the most significant predictors of warfarin dose 
requirements, a linear-regression analysis was performed using Statistical Analysis 
System (SAS) software version 9.4 (SAS® Institute Inc., Cary, NC, USA). The outcome 
variable, average weekly warfarin dose in milligrams was transformed by taking the 
square root of the average weekly warfarin dose. The transformation was incorporated 
to help stabilize the variance in warfarin dose and subscribe to the assumptions of 
normality and linear-regression. The square root normalization of warfarin dose was 
also performed to reflect the accepted approach used by previous generated genotype-
guided warfarin dosing models.37 To further ensure the outcome variable followed 
normal distribution, one patient was excluded due to having an outlier weekly warfarin 
dose requirement of over 100 milligrams. Following square root transformation and 
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exclusion of the dose outlier, three goodness of fit normality tests were performed 
including Kolmogorov-Smirnov (p>0.15), Cramer-von Mises (p=0.217) and Anderson-
Darling (p=0.22). All three normality distribution tests were greater than p-value of 0.05 
which provided confidence that the outcome variable data (square root of weekly 
warfarin dose) was normally distributed. 
To observe how individual variables affected the square root of stable weekly 
warfarin dose, a simple linear-regression analysis was initially performed. Non-genetic 
(i.e. age, gender, height, weight, smoking status, alcohol status, concurrent 
medications, and indications for warfarin therapy) and genetic (i.e. VKORC1-1639A, 
CYP2C9 *2/*3, CYP4F2*3, and NQO1*2) variables were each assessed one by one 
(n=23 variables). Linear-regression outputs determined each variable’s association (p-
value), effect size (regression coefficient), and percentage of variation in warfarin dose 
explained by the predictor variable (R-Square).  
Following simple linear-regression analysis, a multiple stepwise regression 
analysis was performed. The stepwise model automatically controlled for co-variance 
and selected the most significant variables (0.1 p-value cutoff) from the total pool of 
non-genetic and genetic variables available to give a final linear-regression 
pharmacogenetic model. This ensured a potential in clinical bias was avoided and the 
selection of predictor variables were solely based on the strength of significance.  
Stepwise modeling began with the intercept and added individual variables that were 
most significant until the predetermined p-value threshold of 0.1 was reached. During 
each additive step, variables could also be deleted from the model if they rose above 
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the 0.1 p-value. The CYP2C9 variable was defined as either being a *1 or *3 carrier, 
which resulted in a total of 21 variables analyzed.  
Using the pharmacogenetic model developed by the stepwise selection model, 
we compared the warfarin dose predictive performance relative to two other warfarin 
pharmacogenetic studies specific to Mexican Americans.38,39 Additionally, we compared 
the performance of these Hispanic specific algorithms relative to the European-derived 
Gage model.15 The performance of the algorithms was measured by R-square, 
indicating the variation in warfarin stable dose requirements explained by the clinical 
and genetic variables.  
Results  
 
To assess the accuracy of SNP genotyping, 32 of 76 samples were genotyped 
as duplicates across 5 SNPs, which resulted in 100 percent concordance. Next, a 
Hardy-Weinberg equilibrium analysis was performed to determine the expected 
distribution of SNPs within the patient population. The Chi- Square (Χ2 ) test for all 5 
SNPs showed no significant difference between the expected and observed genotype 
frequencies, which further increased the confidence that the genotyped data was 
correct. The allele and genotype frequency distributions with Chi-Square results are 
shown in Table 2.  
Table 2. Genotype and Allele frequency distributions in Hispanic Patients treated at 
Banner Medical Center/El Rio Community Health Center in Tucson, Arizona 
Genotype/allele n (%) Chi-Square Χ2  Χ2  p-value 
VKORC1 -1639G>A  1.42 0.23 
Genotypes 
GG 
 
18 (24.3) 
  
GA 42 (56.8)   
AA 
Allele Frequency 
14 (18.9)   
G 78 (52.7)   
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A 70 (47.3)   
CYP2C9*2  0.48 0.49 
Genotypes 
*1/*1 
 
63 (85.1) 
  
*1/*2 11 (14.9)   
Allele Frequency    
*1 137 (92.6)   
*2 11 (7.4)   
CYP2C9*3  0.06 0.81 
Genotypes    
*1/*1 70 (94.6)   
*1/*3 4 (5.4)   
Allele Frequency    
*1 144 (97.3)   
*3 4 (2.7)   
CYP4F2  0.007 0.93 
Genotypes 
*1/*1 
 
40 (54.0) 
  
*1/*3 29 (39.2)   
*3/*3 
Allele Frequency 
5 (6.8)   
*1 109 (73.6)   
*3 39 (26.4)   
NQO1  2.01 0.16 
Genotypes 
*1/*1 
 
37 (50.0) 
  
*1/*2 34 (46.0)   
*2/*2 
Allele Frequency 
3 (4.0)    
*1 108 (73.0)   
*2 40 (27.0)   
Chi-Square values (≥3.841) or Chi-Square p-values (<0.05) are not consistent with Hardy-
Weinberg equilibrium expectations 
 
The weekly therapeutic warfarin dose ranged from 9.5 mg/week to 70 mg/week. 
The mean weekly warfarin dose was 33.8 mg/week (Table 1) and the derived mean 
daily warfarin dose of 4.8mg/day was similar to previous daily dose averages in 
Hispanic populations at 4.4mg/day.32 The mean age was 65.8 years (range 26-91) and 
55 percent of the patients were male (n=41). The most common indications for warfarin 
therapy included atrial fibrillation (38%, n=38), and deep vein thrombosis (23%, n=24) 
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and the most common concomitant medication was statin use (55%, n=41). In addition 
to self-identifying as Hispanic or Latino, four patients self-identified as having American 
Indian/Alaska Native ancestry. 
In terms of genetic variants, 47 percent of the participants (n=47.3) were carriers 
of the warfarin sensitive VKORC1A allele. The frequencies of warfarin sensitive 
CYP2C9 SNP alleles were 7.4% (n=11) for *2 and 2.7% (n=4) for *3 carriers. The 
warfarin resistant CYP4F2*3 and NQO1*2 SNP alleles had frequency distributions of 
26.4% (n=39) and 27% (n=40), respectively. These minor allele frequencies had similar 
distributions compared to previous Hispanic populations.29 In addition, the VKORC1-
1639A, CYP2C9 *2/*3, and CYP4F2*3 alleles were similar in distribution to previous 
European populations.29 As described previously, all genetic variants were in Hardy-
Weinberg equilibrium.  
The simple linear-regression analysis depicted in Table 3 resulted in a total of 9 
variables that were significant predictors of warfarin dose (p-value <0.05) which 
included weight, BMI, height, age, statin use, amiodarone use, atrial fibrillation 
indication, VKORC1-1639G>A, and CYP2C9 *3/*2 alleles. The clinical effect on warfarin 
dose requirement, measured by the partial regression coefficient, from each variable 
aligned with the expected direction shown in previous studies.37,40 The largest individual 
clinical contributors to warfarin dose variability were weight (R-Square= 28.67%), age 
(R-Square=28.23%), and statin use (R-Square=23.21%). The variability in warfarin dose 
response explained by genetic variables were VKORC1 -1639G>A (R-Square=15.1%), 
and CYP2C9*2/*3 (R-Square=5.98%). The individual clinical contributions to explaining 
warfarin dose variability were relatively higher than previous studies, while the genetic 
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variables followed the proportional contributions in that VKORC1 -1639G>A had a 
greater impact on warfarin dose variability.  
Table 3. Simple Linear Regression analysis of square root of weekly warfarin dose 
(mg/week) in Hispanic Patients treated at Banner Medical Center/El Rio Community 
Health Center in Tucson, Arizona 
Variable P-Value 
Partial 
regression 
coefficient R-Square 
Weight (lbs.) <0.0001 0.0106 0.2867 
BMI <0.0001 0.0611 0.2076 
Age <0.0001 -0.0403 0.2823 
Statin use <0.0001 -1.2275 0.2321 
Atrial Fibrillation 0.0002 -1.0657 0.1765 
VKORC1 -1639G>A 0.0006 -0.7543 0.1510 
Amiodarone use 0.0021 -1.9773 0.1227 
Height (inches) 0.0076 0.1085 0.0950 
CYP2C9 variant *2 or *3 carrier 0.0358 -0.7737 0.0598 
n= 74; VKORC1 was included as an additive predictor with three levels (coded as 0 for GG, 1 
for AG, and 2 for AA); CYP2C9 *2 or *3 carrier status was combined into one variable (coded as 
0 for *1/*1 and 1 for *1/*2 or *3). 
To account for co-variance, a multiple stepwise regression analysis was 
performed. The variables to enter the stepwise model in order of greatest significance 
included weight, VKORC1-1639G>A, age, amiodarone status, CYP2C9 *3/*2, and 
stroke indication. During the analysis no variables were excluded from the stepwise 
model, therefore the final model contained 6 significant predictor variables of warfarin 
dose.  A summary of the stepwise selection algorithm model is shown in Table 4 with 
the individual partial R-square (R2) contributions that explain warfarin dose variability, 
adjusted R2 value, partial regression coefficient that explain the individual clinical effect 
on warfarin dose, and the significance of association to warfarin dose (p-value). The 
highest partial R2 contributions included weight which explained 28.7%, VKORC1-
1639G>A which explained 15.2%, and age which explained 14.3% of variability in 
warfarin dose in the study population. Overall, the 6 variables in the pharmacogenetic 
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model were responsible for explaining a total R2 of 70.6% of the variability in warfarin 
dose (p<0.0001; Table 4). The linear regression model equation for predicting the 
square root of weekly warfarin dose is shown below: 
�𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 � 𝑚𝑚𝑚𝑚
𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤
� = 7.627+ (0.00598 * Weight) – (0.03236 * Age) – 
(0.63506 * CYP2C9) – (0.8686 * VKORC1A) – (1.30079 * amiodarone) – 
(0.69797 * stroke indication) 
Table 4. Multiple Stepwise regression model of square root of weekly warfarin dose 
(mg/week) in Hispanic Patients treated at Banner Medical Center/El Rio Community 
Health Center in Tucson, Arizona 
Step Variables Partial R2 Adjusted R2 
after entry 
Partial regression 
coefficient 
p-value 
1 Weight (lbs.) 0.287 0.2867 0.00598 <0.0001 
2 VKORC1 -
1639G>A 
0.1524 0.4391 -0.86860 <0.0001 
3 Age (years) 0.1426 0.5817 -0.03236 <0.0001 
4 Amiodarone 
status 
0.0674 0.6491 -1.30079 0.0005 
5 CYP2C9 
variant *2 or 
*3 carrier 
0.0315 0.6805 -0.63506 0.0118 
6 Stroke 
Indication 
0.0252 0.7057 -0.69797 0.0193 
Final model R2: 0.7057; n= 74; VKORC1 was included as an additive predictor with three levels 
(coded as 0 for GG, 1 for AG, and 2 for AA); CYP2C9 *2 or *3 carrier status was combined into 
one variable (coded as 0 for *1/*1 and 1 for *1/*2 or *3). 
Discussion 
 
To date, only two studies have evaluated the impact of pharmacogenetics on 
warfarin dose in Mexican Americans.38,39 A comparison of the clinical and genetic 
contributions to warfarin dose variability, in terms of R2, in our cohort vs. the Hispanic 
American specific Cavallari et al. and Bress et al. cohort, as well as the traditional 
European-derived Gage cohort is shown in Table 5.  
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Table 5. Performance of Hispanic Mexican American and Gage European-derived 
Warfarin Pharmacogenetic Dosing Algorithms 
BSA= body surface area; amio= amiodarone; VTE= venous thromboembolism; Afib= atrial 
fibrillation; INR= international normalized ratio; VKORC1= vitamin K epoxide reductase complex 
subunit 1; CYP= cytochrome P450. 
a Addition of CYP4F2*3 and NQO1*2 in the Bress et al. algorithm improved total model R2 to 
68%.  
Incorporation of the primary warfarin predictors VKORC1-1639A and CYP2C9 
*2/*3 improved the R2 warfarin dose prediction over prediction based solely on clinical 
factors in our cohort as well as the Cavallari and Bress Hispanic American cohorts. 
These improvements in prediction were similar to the well-replicated European-based 
Gage cohort, which suggests using this algorithm may be appropriate in Mexican 
American populations. The study performed by Cavallari et al., found the common 
European VKORC1 and CYP2C9 genotypes were sufficient in predicting warfarin dose 
requirements. When the genotypes were combined with clinical variables, the factors 
explained 55% of the variability in warfarin dose which corresponds with data in 
Study 
algorithm 
Race/Ethnicity n Genetic 
Variables 
Clinical 
Variables 
Genetic & 
Clinical 
Algorithm (R2 ) 
Clinical 
Variables (R2 ) 
Banner/El-
Rio Cohort   
Mexican 
American- 
Tucson 
74 VKORC1-
1639A 
CYP2C9 
*2, *3 
Age, 
weight, 
amio, 
stroke 
71% 53% 
Cavallari et 
al. 201139 
 
Mexican 
American- 
Chicago 
55 VKORC1-
1639A 
CYP2C9 
*2, *3 
Age, BSA, 
VTE 
55% 17% 
Bress et al. 
201238 
Mexican 
American- 
Chicago 
50 VKORC1-
1639A 
CYP2C9 
*2, *3 
Age, BSA, 
Afib 
58%a 36% 
Gage et al. 
200815 
White (83%) 
AA (15%) 
Mixed (2%) 
1015 VKORC1-
1639A 
CYP2C9 
*2, *3 
Age, BSA, 
target INR, 
amio, race, 
smoking, 
VTE 
53% 17% 
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Europeans, where these variables explain an estimated 50-60% of the dose variability 
(Gage is 53% shown in Table 5).15,28 However, the study did not look into identifying 
ethno-specific variants that may further contribute to warfarin dose response. As shown 
in the study by Bress et al., the addition of CYP4F2*3 and NQO1*2 genotypes improved 
the overall explanation in dose variability in Hispanic Americans from 58% to 68% 
(Table 5).38 
Herein, we selected the candidate gene variants in VKORC1, CYP2C9, CYP4F2, 
NQO1, and additional clinical factors known to effect warfarin dose in Hispanic 
populations. The final stepwise regression model in our cohort was able to explain 71% 
of the variability in warfarin dose response (Table 4 and 5). Although our overall R2 
prediction value has the highest performance in explaining variability in warfarin dose, 
the genetic contribution at 18% was relatively low in comparison and may suggest the 
need to identify additional genetic contributors associated with warfarin dose. The only 
significant genotypes to make it into the final model were VKORC1 -1639G>A and 
CYP2C9*2/*3 which is in line with the findings of Cavallari et al. and the larger 
European-based IWPC and Gage algorithm studies.15,37,39 However, this statement is 
made with the caveat that in addition to our cohort only the Bress et al. study 
considered the additional NQO1*2 and CYP4F2*3 allele variants.38  
In contrast to Bress et al., the NQO1 and CYP4F2 genotypes in our cohort were 
non-significant and were not included in the stepwise model despite the similar 
prevalence of these variants (minor allele frequencies (MAF), NQO1*2 MAF is 27% in 
both cohorts; CYP4F2*3 MAF is 26% in our cohort vs 23% in Bress cohort). Although 
our cohort did not find significant warfarin dose associations with these two SNPs, most 
   
 
35 
 
of the highly associated variables that made it in the final stepwise model reflect the 
expected variables that explain warfarin dose as validated in previous studies.15,41  
The clinical effect on increasing or decreasing dose requirements for each 
variable (Partial regression coefficient in Table 4) also aligns with the expected direction 
seen in the previous warfarin pharmacogenetic literature.37,40 Most notably, although the 
NQO1*2 allele did not make it into to the final model, there was an increased effect on 
warfarin dose requirements as similarly observed in the Bress et al. study.38 This may 
indicate the differences in statistical significance could be due to a false positive 
association in the Bress et al., or a false-negative in our findings since our cohort did not 
replicate the association. Nevertheless, the increase in effect of NQO1*2 on warfarin 
dose requirements in both cohorts is in contrast to non-Hispanic populations, which may 
suggest alternate causative variants have yet to be determined in Hispanic populations 
that properly predict dose requirements.  
In terms of limitations, our study cohort was relatively small with a sample size of 
74 patients. The final prediction variables and their effect on warfarin dose generated 
from the final stepwise model have also not been replicated and validated in an 
independent population. Patients self-reported their race/ethnicity and we did not 
conduct a genotype-based estimation of ancestry.  In addition, a direct comparison 
between our Hispanic population and previously published literature is difficult 
considering the highly diverse nature of this ethnic group.  Lastly, the stepwise model 
characterized the indication of stroke as a significant clinical predictor which has not 
been found as a significant factor in explaining dose in previous studies. This variable 
may be characterizing the fact that our cohort has a higher mean age at 66 years as 
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stroke is more common in elderly patients. The association could reflect a lower dose 
requirement which is positively correlated with age.  
Future Directions 
The potential to improve patient outcomes by more accurately predicting the 
correct warfarin dose requirement remains high. It is a reasonable rationale that 
accurate predictions during warfarin initiation should reduce the time it takes to arrive at 
a therapeutic INR level and thus reduce the risks of warfarin-related adverse events 
such as major bleeding or thrombosis. A recent large multi-site clinical trial of 1650 
patients published in JAMA (GIFT trial), found this to be the case, in which genotype-
guided dosing more accurately predicted warfarin dose compared to clinically-guided 
dosing. This led to a reduction in adverse events of primary outcomes in major bleeding 
and venous thromboembolism.40  
Because of the high susceptibility Hispanic patients encounter in terms of 
warfarin related adverse events30,31, the potential to better understand how genetic 
variation contributes to warfarin variability in Hispanic populations is critical.  To meet 
these goals, our next step in the clinical study will involve a similar candidate SNP study 
as part of a broader Hispanic Warfarin Pharmacogenetic Consortium. The replication 
studies will be conducted at clinical academic institutions in Florida, Illinois, Puerto Rico, 
and Brazil, which will provide further evidence as to whether a non-Hispanic 
pharmacogenetic dosing strategy or a more Hispanic-specific algorithm is appropriate to 
guide warfarin initiation.  
In addition, due to the unique admixture within Hispanic and Latino populations, 
we plan to properly define the genetic structure of our cohort by genotyping ancestry 
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informative markers to estimate Native American, European, and African ancestry 
proportions. Ancestry may be included as a variable in a final revised dosing model 
along with clinical and genetic factors to further improve dose prediction. Because our 
study only evaluated clinical and genetic factors derived from one Hispanic American 
specific study (Bress et al.) and a study with the majority population of European 
ancestry (GAGE model), we will evaluate the potential of additional or undefined 
variants that may contribute to explaining warfarin dose.15,38 A genome-wide association 
study will be conducted to identify novel associations with warfarin stable dose 
requirements across a broad range of genomic variation.  
Conclusions 
In this present study we aimed to identify whether clinical factors and SNPs 
previously associated with stable warfarin dose variability in populations of European 
and Hispanic descent, accurately predicted dose in a Hispanic population. Findings 
from our linear regression model indicate genetic and clinical predictors of stable 
warfarin dose variability may be similar among populations of European and Hispanic 
ancestry. The recent updated Clinical Pharmacogenomics Implementation Consortium 
(CPIC) guidelines for genotype-guided warfarin dosing reflect our findings in terms of 
dosing recommendations based on race/ethnicity.41 These recommendations for 
pharmacogenetic dosing of warfarin recommend we treat patients with African ancestry 
differently based on their SNP data and all other race/ethnic groups the same. Our 
results suggest that this is a valid approach in that Hispanics and European patients 
may potentially be treated similarly using classic SNP data from the common IWPC and 
Gage algorithms. These findings from our cohort study further add to the understanding 
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of how genetic variation influences warfarin dose in Hispanic American populations. We 
hope this clinical study will serve to help guide pharmacogenetic warfarin dosing 
strategies that focus on improving warfarin therapy and patient outcomes. Further 
studies will be needed to replicate and validate these findings in other Hispanic 
populations.
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